Lantheus presented results from two pivotal phase III studies that used florquinitau F-18 (Tauklarify), the company's tau PET imaging agent, at the Clinical Trials on Alzheimer’s Disease (CTAD) 2026 meeting in Boston.
The studies evaluated 617 PET scans using a prospectively defined reference standard, in which amyloid beta PET-positive individuals with cognitive impairment were classified as having tau pathology and age-matched amyloid beta-negative, cognitively normal individuals were classified as not having it. All five independent readers met the co-primary endpoints in both studies, according to the company.
In one study, reader sensitivity ranged from 79.9% to 88.5% and specificity from 97.9% to 99.3%. In another study, sensitivity ranged from 68.2% to 82.4% and specificity from 93.5% to 99.4%. The studies achieved high inter-reader agreement, with Fleiss’ kappa values of 0.92 and 0.86, respectively.
The studies supported U.S. Food and Drug Administration (FDA) approval of florquinitau F-18 for PET imaging of the brain in adults with cognitive impairment being evaluated for Alzheimer’s disease to identify tau neurofibrillary tangle pathology, Lantheus said.



















